RemeGen Co., Ltd. (OTCMKTS:REGMF) Short Interest Update

RemeGen Co., Ltd. (OTCMKTS:REGMF) saw a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 70,500 shares, a decrease of 62.9% from the January 15th total of 190,000 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.

RemeGen Price Performance

RemeGen stock opened at $10.45 on Wednesday. The company has a fifty day simple moving average of $10.05 and a 200-day simple moving average of $8.89. RemeGen has a 12-month low of $9.81 and a 12-month high of $15.91.

About RemeGen

RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.

RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.